DNA X Statistics
Total Valuation
DNA X has a market cap or net worth of $10.43 million. The enterprise value is $13.36 million.
Important Dates
The next estimated earnings date is Monday, March 30, 2026, after market close.
| Earnings Date | Mar 30, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
DNA X has 1.49 million shares outstanding. The number of shares has increased by 107.24% in one year.
| Current Share Class | 1.49M |
| Shares Outstanding | 1.49M |
| Shares Change (YoY) | +107.24% |
| Shares Change (QoQ) | +86.41% |
| Owned by Insiders (%) | 3.60% |
| Owned by Institutions (%) | 8.93% |
| Float | 1.33M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.06 |
| Forward PS | 0.25 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.23 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.78
| Current Ratio | 0.78 |
| Quick Ratio | 0.40 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -31.22 |
Financial Efficiency
Return on equity (ROE) is -455.82% and return on invested capital (ROIC) is -3,507.70%.
| Return on Equity (ROE) | -455.82% |
| Return on Assets (ROA) | -44.28% |
| Return on Invested Capital (ROIC) | -3,507.70% |
| Return on Capital Employed (ROCE) | -2,322.60% |
| Weighted Average Cost of Capital (WACC) | 13.98% |
| Revenue Per Employee | $451,214 |
| Profits Per Employee | -$254,840 |
| Employee Count | 131 |
| Asset Turnover | 1.32 |
| Inventory Turnover | 3.80 |
Taxes
In the past 12 months, DNA X has paid $308,000 in taxes.
| Income Tax | 308,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -85.73% in the last 52 weeks. The beta is 1.61, so DNA X's price volatility has been higher than the market average.
| Beta (5Y) | 1.61 |
| 52-Week Price Change | -85.73% |
| 50-Day Moving Average | 5.04 |
| 200-Day Moving Average | 12.19 |
| Relative Strength Index (RSI) | 62.26 |
| Average Volume (20 Days) | 63,360 |
Short Selling Information
The latest short interest is 72,446, so 4.87% of the outstanding shares have been sold short.
| Short Interest | 72,446 |
| Short Previous Month | 82,334 |
| Short % of Shares Out | 4.87% |
| Short % of Float | 5.46% |
| Short Ratio (days to cover) | 1.06 |
Income Statement
In the last 12 months, DNA X had revenue of $59.11 million and -$33.38 million in losses. Loss per share was -$63.08.
| Revenue | 59.11M |
| Gross Profit | 10.59M |
| Operating Income | -31.66M |
| Pretax Income | -33.08M |
| Net Income | -33.38M |
| EBITDA | -28.27M |
| EBIT | -31.66M |
| Loss Per Share | -$63.08 |
Full Income StatementBalance Sheet
The company has $2.14 million in cash and $5.07 million in debt, with a net cash position of -$2.93 million or -$1.97 per share.
| Cash & Cash Equivalents | 2.14M |
| Total Debt | 5.07M |
| Net Cash | -2.93M |
| Net Cash Per Share | -$1.97 |
| Equity (Book Value) | -701,000 |
| Book Value Per Share | -0.69 |
| Working Capital | -8.56M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$26.03 million and capital expenditures -$8,000, giving a free cash flow of -$26.04 million.
| Operating Cash Flow | -26.03M |
| Capital Expenditures | -8,000 |
| Free Cash Flow | -26.04M |
| FCF Per Share | -$17.50 |
Full Cash Flow StatementMargins
Gross margin is 17.91%, with operating and profit margins of -53.56% and -56.48%.
| Gross Margin | 17.91% |
| Operating Margin | -53.56% |
| Pretax Margin | -55.96% |
| Profit Margin | -56.48% |
| EBITDA Margin | -47.83% |
| EBIT Margin | -53.56% |
| FCF Margin | n/a |
Dividends & Yields
DNA X does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -107.24% |
| Shareholder Yield | -107.24% |
| Earnings Yield | -319.99% |
| FCF Yield | -249.59% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on October 27, 2025. It was a reverse split with a ratio of 1:18.
| Last Split Date | Oct 27, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:18 |
Scores
DNA X has an Altman Z-Score of -11.47 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -11.47 |
| Piotroski F-Score | 2 |
